These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 15800820)

  • 1. [Comparison of different stool tests for the detection of cancer of the colon].
    Vogel T; Driemel C; Hauser A; Hansmann A; Lange S; Jonas M; Möslein G
    Dtsch Med Wochenschr; 2005 Apr; 130(14):872-7. PubMed ID: 15800820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
    J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms.
    Rozen P; Levi Z; Hazazi R; Waked A; Vilkin A; Maoz E; Birkenfeld S; Niv Y
    Aliment Pharmacol Ther; 2009 Feb; 29(4):450-7. PubMed ID: 19035980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population.
    Graser A; Stieber P; Nagel D; Schäfer C; Horst D; Becker CR; Nikolaou K; Lottes A; Geisbüsch S; Kramer H; Wagner AC; Diepolder H; Schirra J; Roth HJ; Seidel D; Göke B; Reiser MF; Kolligs FT
    Gut; 2009 Feb; 58(2):241-8. PubMed ID: 18852257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study.
    Hoepffner N; Shastri YM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein J
    Aliment Pharmacol Ther; 2006 Jan; 23(1):145-54. PubMed ID: 16393292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validity of new immunological human fecal hemoglobin and albumin tests in detecting colorectal neoplasms--an endoscopy-controlled study.
    Sieg A; Scheida M; John MR; Hertel A; Schröter M; Lüthgens K; Schmidt-Gayk H
    Z Gastroenterol; 1998 Jun; 36(6):485-90. PubMed ID: 9675833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stool test for colorectal cancer screening--it's time to move!
    Loitsch SM; Shastri Y; Stein J
    Clin Lab; 2008; 54(11-12):473-84. PubMed ID: 19216253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal pyruvate kinase-M2 (tumor M2-PK) measurement: a new screening concept for colorectal cancer.
    Ewald N; Schaller M; Bayer M; Akinci A; Bretzel RG; Kloer HU; Hardt PD
    Anticancer Res; 2007; 27(4A):1949-52. PubMed ID: 17649802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls.
    Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
    Anticancer Res; 2003; 23(2A):851-3. PubMed ID: 12820312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testing of multiple samples increases the sensitivity of stool decay-accelerating factor test for the detection of colorectal cancer.
    Mizuno M; Mizuno M; Iwagaki N; Nasu J; Okazaki H; Yamamoto K; Okada H; Tsuji T; Fujita T; Shiratori Y
    Am J Gastroenterol; 2003 Nov; 98(11):2550-5. PubMed ID: 14638362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
    van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
    Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fecal occult blood--does a hemoglobin-specific tests improve the diagnosis of relevant colonic neoplasms?].
    Gysi B; Lang C; Affolter H
    Schweiz Med Wochenschr; 1991 Jun; 121(26):988-90. PubMed ID: 1862316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
    Smith A; Young GP; Cole SR; Bampton P
    Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data].
    Ewald N; Toepler M; Akinci A; Kloer HU; Bretzel RG; Hardt PD
    Z Gastroenterol; 2005 Dec; 43(12):1313-7. PubMed ID: 16315127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new immunological test strip device for the rapid, qualitative detection of faecal occult blood.
    Trojan J; Povse N; Schröder O; Stein J
    Z Gastroenterol; 2002 Nov; 40(11):921-4. PubMed ID: 12436369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test.
    Levi Z; Hazazi R; Rozen P; Vilkin A; Waked A; Niv Y
    Aliment Pharmacol Ther; 2006 May; 23(9):1359-64. PubMed ID: 16629942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed.
    Rozen P; Levi Z; Hazazi R; Waked A; Vilkin A; Maoz E; Birkenfeld S; Leshno M; Niv Y
    Aliment Pharmacol Ther; 2009 Apr; 29(8):906-17. PubMed ID: 19183147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New stool screening tests for colorectal cancer.
    Young GP; Cole S
    Digestion; 2007; 76(1):26-33. PubMed ID: 17947816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy.
    Sobhani I; Alzahouri K; Ghout I; Charles DJ; Durand-Zaleski I
    Dis Colon Rectum; 2011 Jul; 54(7):876-86. PubMed ID: 21654256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colon cancer screening strategies.
    Agrawal J; Syngal S
    Curr Opin Gastroenterol; 2005 Jan; 21(1):59-63. PubMed ID: 15687886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.